Format

Send to

Choose Destination

[Clinical research of xinganbao capsule on the treatment of chronic hepatitis B liver fibrosis].

[Article in Chinese]

Author information

1
Department of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing 100015.

Abstract

OBJECTIVE:

To explore the effects of Xinganbao Capsule (Cordyceps Sinensis) on the chronic hepatitis B liver fibrosis.

METHODS:

Sixty patients with chronic hepatitis B were randomly assigned to the trail group (40 cases) and the control group (20 cases). The trail group was treated with Xinganbao Capsule, 8 capsules each time, three times a day. The control group was given Heluo Shugan Tablet, 5 pills each time, thrice daily. Six months consisted of one therapeutic course. The liver function, four indicators of serum fibrosis, liver histology, and other items were detected.

RESULTS:

Xinganbao Capsule could reduce serum ALT and AST levels, serum HA, PC-III and LN levels (all P<0.05), showing statistical difference when compared with before treatment. The HA and LN levels decreased more significantly in the control group when compared with before treatment (P<0.05). Totally 21 patients (53% of the recruited cases) in the trial group completed the liver biopsy twice. After treated with Xinganbao Capsule, 81% patients (17/21) had decreased liver inflammation 1 grade or more, 52% patients (11/21) had decreased fibrosis staging one or more, and 33% (7/21) patients had no change in fibrosis.

CONCLUSION:

Xinganbao Capsule could improve the liver function, reduce liver inflammation, and fight against hepatic fibrosis.

PMID:
22686076
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center